Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 1998

View Archived Issues

Estrogen: a potential agent for prevention of dementia?

COX-1 inhibition is more effective than COX-2 inhibition in a chronic inflammation model

Company Profile: Sinogen

Dusa: year-end 1997 highlights

Potent inhibitors of IL-1beta and TNF-alpha production prepared at Nisshin Flour Milling

Abbott describes novel lead structure for selective COX-2 inhibitors

AHP reports novel neuroprotectants

Company Profile: SuperGen

U.S. university scientists report novel muscarinic agonists

BB-10010 has myelosuppressive and progenitor cell-mobilizing effects in humans

LXR files IND for CP-Cardiosol

Analysis of statin results confirms beneficial clinical effects of lipid lowering on mortality

Phase II ImmTher trial begins in pediatric cancer patients

FDA clears free PSA blood test

LifeCell will be awarded U.S. patent for blood cell preservation technology

Mechanism of chemopreventive activity of resveratrol identified

GABA-A receptor ligands under evaluation at Neurogen

Ixion succeeds in lowering urinary oxalate levels with IxC1-62/47

Creative BioMolecules: year-end 1997 highlights

Fuisz closes acquisition of Rentschler

SmithKline Beecham and Ligand begin leptin-obesity collaboration

Spongiform encephalopathies advisory committee meeting scheduled

Collagenex amends NDA for Periostat

Roche benzodiazepines go head-to-head with midazolam

CytRx begins patient enrollment for Flocor phase III trial

Combivir approved in E.U.

Novel enzyme inhibitors discovered at California institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...